Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00091273
Other study ID # 11276
Secondary ID UVACC-OVA3UVACC-
Status Completed
Phase Phase 1
First received September 7, 2004
Last updated May 19, 2014
Start date June 2004
Est. completion date June 2007

Study information

Verified date May 2014
Source University of Virginia
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with ovarian epithelial or primary peritoneal cancer.


Description:

OBJECTIVES:

- Determine the safety and immunogenicity of adjuvant vaccine comprising ovarian cancer synthetic peptides, tetanus toxoid helper peptide, and sargramostim (GM-CSF) emulsified in Montanide ISA-51 in patients with previously treated ovarian epithelial or primary peritoneal cancer.

OUTLINE: This is an open-label study.

Patients receive vaccine comprising ovarian cancer synthetic peptides, tetanus toxoid helper peptide, sargramostim (GM-CSF), and Montanide ISA-51 subcutaneously and intradermally to 2 different sites on days 1, 8, and 15. On day 22, patients undergo removal of the lymph node draining the vaccination site to determine whether the immune system is responding to the vaccine. Patients then receive additional vaccine as above only to the primary vaccination site on days 29, 36, and 43.

After completion of study treatment, patients are followed at 1 week, 1 month, every 3 months for 9 months, every 6 months for 1 year, and then annually thereafter.

PROJECTED ACCRUAL: A maximum of 9 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date June 2007
Est. primary completion date February 2006
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed ovarian epithelial or primary peritoneal cancer

- Completed primary therapy (surgery and chemotherapy for newly diagnosed disease) within the past 12 months and meets 1 of the following criteria:

- Clinical or radiographic evidence of disease

- Serologic evidence of disease

- Initial diagnosis of stage III or IV disease AND completed anticancer therapy within the past 12 months

- At least 2 intact axillary and/or inguinal lymph node basins

- Prior lymph node biopsy allowed provided lymphoscintigraphy demonstrates intact drainage to a node in that basin

- HLA-A1-, -A2-, or -A3-positive

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- GOG 0-2

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count > 1,500/mm^3

- Hemoglobin > 8.0 g/dL OR

- Hematocrit > 25%

- Platelet count = 80,000/mm^3

Hepatic

- AST and ALT = 2.5 times upper limit of normal

- Hepatitis C negative

Renal

- Not specified

Cardiovascular

- No New York Heart Association class III or IV heart disease

Immunologic

- HIV negative

- No active infection requiring antibiotics

- No prior or active autoimmune disorder requiring cytotoxic or immunosuppressive therapy

- No prior autoimmune disorder with visceral involvement

- No known or suspected allergy to any component of the study vaccine

- The following immunologic conditions are allowed:

- Laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody titer) that is asymptomatic

- Clinical evidence of vitiligo or other forms of depigmenting illness

- Mild arthritis requiring non-steroidal anti-inflammatory drugs

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Weight = 110 lbs

- No uncontrolled diabetes, defined as hemoglobin A1C = 7%

- No active hyperthyroidism

- No current or recent (within the past year) addiction to alcohol or drugs

- No medical contraindication or other potential medical problem that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

- More than 2 weeks since prior and no concurrent allergy desensitization injections

- More than 2 weeks since prior and no concurrent growth factors (e.g., epoetin alfa or pegfilgrastim)

- More than 1 month since prior and no other concurrent immunotherapy

- More than 2 weeks since prior and no other concurrent potential immunomodulating agents, including any of the following:

- Interferon

- Tumor necrosis factor

- Interleukins or other cytokines

- Biologic response modifiers

- Monoclonal antibodies

- No prior vaccination with all of the study peptides relevant to the patient's HLA-type

Chemotherapy

- See Disease Characteristics

- More than 1 month since prior chemotherapy and recovered

- No concurrent cytotoxic chemotherapy

Endocrine therapy

- More than 2 weeks since prior and no concurrent parenteral or oral corticosteroids (e.g., prednisone or albuterol)

- Topical corticosteroids allowed

Radiotherapy

- More than 1 month since prior radiotherapy and recovered

Surgery

- See Disease Characteristics

- More than 1 month since prior surgery and recovered

Other

- More than 1 month since other prior treatment and recovered

- More than 1 month since prior and no other concurrent investigational agents

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Biological:
incomplete Freund's adjuvant

ovarian cancer peptide vaccine

sargramostim

tetanus toxoid helper peptide

Procedure:
adjuvant therapy


Locations

Country Name City State
United States University of Virginia Cancer Center Charlottesville Virginia

Sponsors (2)

Lead Sponsor Collaborator
University of Virginia National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the Vaccine Participants kept a toxicity diary during the time frame of interest which was reviewed with a study clinician at each visit. Days 1,8,15,22,29,36,43,50 Yes
Primary Measure of Tumor-antigen-specific Immunity in SIN by ELIspot Assay Day 22 No
Secondary Measure of Tumor-antigen-specific Immunity in PBMC by Elispot Assay Days 1,8,15,22,29,36,43,50 and Month 3 No
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2